Search This Blog

Thursday, July 30, 2026

Agios sells off after Q2 despite Priority Review to mitapivat sNDA for sickle cell disease

 

Agios Q2 2026 revenue $44.7M (+258% YoY) beats estimates as FDA grants Priority Review to mitapivat sNDA for sickle cell disease

  • Q2 2026 non-GAAP EPS was $-1.69, improving 12% YoY but still below earnings estimates.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)